Compass Therapeutics (CMPX) plunges 53% as COMPANION-002 overall-survival data disappoint

Compass Therapeutics (CMPX) is down 53.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied to the company’s April 27 update from the Phase 2/3 COMPANION-002 study in second-line biliary tract cancer, where overall survival was not statistically improved despite a meaningful progression-free survival benefit. For a late-stage oncology program, investors often weight overall survival heavily, so the lack of OS separation likely reset expectations for regulatory and commercial outcomes.

Details:

The company disclosed that median progression-free survival improved to 4.7 months with tovecimig plus paclitaxel versus 2.6 months with paclitaxel alone, reaching statistical significance.

Overall survival in the intent-to-treat analysis was not statistically different (8.9 months vs. 9.4 months), and the reported hazard ratio did not favor the combination.

The company reiterated the previously announced primary endpoint result showing a higher overall response rate for the combination (17.1%) versus control (5.3%).

Compass held a webcast the morning of April 27 to review the topline secondary endpoints and noted plans to engage U.S. regulators in the coming months.

Sources:

Compass Therapeutics Investor Relations, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive CMPX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$CMPX Hedge Fund Activity

We have seen 108 institutional investors add shares of $CMPX stock to their portfolio, and 48 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MPM BIOIMPACT LLC removed 5,075,970 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $27,257,958
BLACKSTONE INC. removed 3,713,926 shares (-37.7%) from their portfolio in Q4 2025, for an estimated $19,943,782
DEERFIELD MANAGEMENT COMPANY, L.P. added 3,606,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,364,220
BVF INC/IL added 3,014,842 shares (+63.5%) to their portfolio in Q4 2025, for an estimated $16,189,701
BRAIDWELL LP added 2,786,778 shares (+inf%) to their portfolio in Q4 2025, for an estimated $14,964,997
PALO ALTO INVESTORS LP added 2,532,419 shares (+inf%) to their portfolio in Q4 2025, for an estimated $13,599,090
RTW INVESTMENTS, LP added 2,500,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $13,425,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$CMPX Analyst Ratings

Wall Street analysts have issued reports on $CMPX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

D. Boral Capital issued a "Buy" rating on 01/06/2026
William Blair issued a "Outperform" rating on 01/05/2026
Canaccord Genuity issued a "Buy" rating on 12/03/2025
Cantor Fitzgerald issued a "Overweight" rating on 12/03/2025

To track analyst ratings and price targets for $CMPX, check out Quiver Quantitative's $CMPX forecast page.

$CMPX Price Targets

Multiple analysts have issued price targets for $CMPX recently. We have seen 4 analysts offer price targets for $CMPX in the last 6 months, with a median target of $11.0.

Here are some recent targets:

Jason Kolbert from D. Boral Capital set a target price of $30.0 on 04/27/2026
Michael Schmidt from Guggenheim set a target price of $12.0 on 03/24/2026
John Newman from Canaccord Genuity set a target price of $10.0 on 12/03/2025
Reni Benjamin from Citizens set a target price of $10.0 on 12/03/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.